STK11 and non-small cell lung carcinoma: In non-small-cell lung cancer (NSCLC), pathogenic STK11 mutations are associated with poor prognosis in the KRAS-mutated subtype and have emerged as predictive biomarkers for primary resistance to ICIs [19, 20].